Virtual Library
Start Your Search
Lin Zhi Xuan
Author of
-
+
P1.01 - Advanced NSCLC (ID 757)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.01-078 - Longitudinal Studies of Quality of Life in Advanced Non-Small Cell Lung Cancer Patients Undergoing First-Line Target Therapy (ID 7871)
09:30 - 09:30 | Presenting Author(s): Lin Zhi Xuan
- Abstract
Background:
This paper studies the quality of Life (QoL) of taiwan advanced non-small-cell lung cancer (NSCLC) patients receiving first-line target therapy; QoL data into sexual scores using the European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire EORTC QLQ-C30 and the QLQ-13 in patients with NSCLC.
Method:
From March 2016 to March 2017, patients with in a teaching hospital in southern Taiwan were recruited as the research participants, the patients with advanced or metastatic EGFR mutation-positive NSCLC who received gefitinib, erlotinib, or afatinib as first-line treatment, were invited to complete the EORTC QLQ-C30 and QLQ-C13 on a 5 time visit, the data was analyzed by using SPSS 20.0 software.
Result:
A total of 30 patients with NSCLC, The global health status showed differences between QOL before Target therapy and 4 and 12 weeks after commencing therapy, compared to baseline. Quality of life-30 scores were 35.6 ± 8.3 before therapy, 38.1 ± 7 after 4 weeks and 43.4 ± 6.8 after 12 weeks (P <0.000)(Table 1). For the other scales, at 12 weeks, improvement of insomnia, Pain, Dyspnoea, Fatigue and Appetite loss, but worsening of diarrhea, Sore mouth and Dysphagia were observed (P <0.05).
Conclusion:
Longitudinal QoL assessments are important in advanced lung cancer patients because the data they provide could, for example, help to assess more patient areas and enable early recognition of arising symptom aggravation, there support for case management and health education.Figure 1
-
+
P1.10 - Nursing/Palliative Care/Ethics (ID 696)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Nursing/Palliative Care/Ethics
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.10-006 - Adverse Events After First-Line Target Therapy for Non-Small Cell Lung Cancer Patients in a Case Management Model (ID 7306)
09:30 - 09:30 | Presenting Author(s): Lin Zhi Xuan
- Abstract
Background:
The application of integrated cancer treatment has improved the Nursing quality of patients with cancer. Therefore, recently the case management model has been actively implemented in Taiwan to achieve synergy between resource, communication, and coordination. By using the case management model as an analytic framework, Therefore, this study aimed to identify reasonssevere adverse events (AEs) of three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in Non-Small Cell Lung Cancer(NSCLC) patients with EGFR mutant.
Method:
From January 2014 to December 2015, patients with lung cancer treated in a teaching hospital in southern Taiwan were recruited as the research participants, retrospectively analyzed the patients with advanced or metastatic EGFR mutation-positive NSCLC who received gefitinib, erlotinib, or afatinib as first-line treatment.
Result:
The analysis median age of the 88 patients (37 males, 51 females) was 63 years (range, 29-94 years). Sixty-two patients (70%) never smoked. 84 (95%) had adenocarcinoma(Table 1). Common adverse events in all three EGFR-TKIs included rash, diarrhea and liver dysfunction, mainly grade 3 or 4 toxicity, including rash (10.2%), diarrhea (11.4%) and hepatotoxicity (6.8%). the total frequency of AE that resulted in treatment withdrawal was 12.5%. Rash and diarrhea were the most common drug-related toxicities, of the 21.6% (19 out of 88) consult dermatology, among them females the most, fifteen patients (78.9%,15 out of 19) at dermatology for rash treatment.Figure 1
Conclusion:
First-line targeted therapy is the preferred standard of care for patients with advanced EGFR mutations in advanced NSCLC. a lack of adequate understanding of the disease and treatment by patients or family members. There support for case management and health education, patients can get more comprehensive treatment and Improvements to problems associated with cessation of treatment.
-
+
P2.03 - Chemotherapy/Targeted Therapy (ID 704)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.03-001 - Survivors and Adverse Events After First-Line Target Therapy for Advanced Non-Small Cell Lung Cancer Patients in Taiwan (ID 7305)
09:30 - 09:30 | Presenting Author(s): Lin Zhi Xuan
- Abstract
Background:
Some patients with advanced non-small cell lung cancer (NSCLC) show prolonged disease stabilization on treatment with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib, erlotinib and afatinib provide remarkable response rates and survival in NSCLC patients harboring epidermal growth factor receptor-activating mutations, and are therefore standard first-line treatment in these patients, given the long-term exposure of such patients to EGFR-TKIs, from those observed in patients, to evaluate the efficacy and antitumor activity and toxicity, this study aimed to compared reasons severe adverse events (AEs) and survivors for NSCLC patients treated with these three EGFR-TKIs.
Method:
We conducted this retrospective study at a single teaching hospital in southern Taiwan from January 2014 to December 2015, the patients with advanced or metastatic EGFR mutation-positive NSCLC who received gefitinib, erlotinib, or afatinib as first-line treatment, used the Kaplan-Meier method to estimate survival, the data was analyzed by using SPSS 20.0 software.
Result:
Of the 192 patients diagnosed with stage IIIB and IV NSCLC(Non-squamous) in the study period, the analysis 88 (45.8%) had EGFR-activating mutations, of the 37 males, 51 females, median age was 63 years (range, 29-94 years). Sixty-two patients (70%) never smoked. 84 (95%) had adenocarcinoma,and received first-line therapy with gefitinib (n = 55, 63%), erlotinib (n = 10, 11%), and afatinib (n = 23, 26%).Rash and diarrhea were the most common drug-related toxicities, encountered in 68.2% and 53.4% of patients, The overall response and disease control rates were 58 and 80 %(Table 1), respectively, and the median progression-free survival and overall survival were 16 and 23 months, respectively. Figure 1
Conclusion:
First-line target therapy a preferred standard treatment in advanced NSCLC harboring sensitive EGFR mutations. treatment with TKI was feasible and lead to prolonged overall survival.
